Court Decision Strengthens FDA's Regulatory Power

By Farley, Dixie | FDA Consumer, September 1993 | Go to article overview

Court Decision Strengthens FDA's Regulatory Power


Farley, Dixie, FDA Consumer


In a landmark regulatory action initiated by FDA, a federal court in New Jersey ordered a major generic drug manufacturer to recall millions of its tablets and other drug products. The court found these products had failed to meet quality requirements.

FDA initiated the action under the Federal Food, Drug, and Cosmetic Act. To take such items off the market in the past, either the involved firm voluntarily recalled the products, or FDA requested courts to order seizure by U.S. marshals --provided the agency could find the products. Now, with this precedent-setting decision, FDA can ask the court to order the responsible firms to recall.

After a long hearing at which five industry experts, an FDA investigator, and several company employees testified, Judge Alfred M. Wolin, U.S. District Judge for the District of New Jersey, issued a 79-page opinion last February in the case of Barr Laboratories, Inc., of Northvale, N.J., and Pomona, N.Y.

The recalled drugs are various analgesics and antibiotics. Listed with the numbers of their recalled batches in parentheses, the products are: * aspirin with codeine 325/60-milligram tablets (1C280DY) * erythromycin delayed-release 250-mg capsules (1F584EV) * erythromycin ethylsuccinate 400-mg tablets (OB259FA) * erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension, 200 mg/600 mg (1H445DQ, 1I445EF) * erythromycin stearate 240-mg tablets (O1013FQ) * erythromycin stearate 500-mg tablets (2A219HJ) * hydrocodone bitartrate with APAP 5 mg/500-mg tablets (1D325CL) * meperidine HCl 50-mg tablets (OB381AO, OB381AT, OB381AW, OB381AV).

The court also ordered Barr to stop distributing 24 of its products that had a history of manufacturing deficiencies until the firm validated their manufacturing processes. Barr must demonstrate to the satisfaction of FDA and the court that these processes will reliably yield drugs conforming to required potency and quality characteristics. Only after Barr does this may it resume the drugs' release.

Barr must also perform validation studies on 15 additional drug products, although these products have not been suspended in the interim. All the validation studies must be completed within one year.

In addition, Barr must immediately put into place a wide range of manufacturing and drug-testing controls and explain any gaps in its validation testing. For example, it must: * document the reason for excluding a batch from testing * investigate the reasons for a failed batch before resampling it for testing again * produce a study to validate that the firm's regular cleaning procedures actually clean its milling machine * identify the cleaning agents used in all its cleaning validation studies * record individual test results, not just averages * base product release on all results, not just averages.

Judge Wolin's decision follows four years of increasingly widespread manufacturing deficiencies reported by FDA investigators reviewing Barr's practices and products during inspections. The reported problems include misplaced records, test data recorded on scrap paper, failure to control manufacturing steps such as those governing products' physical properties, release of products not meeting their specifications, inadequate investigation of failed products, and failure to validate test methods and manufacturing processes, including cleaning processes.

On behalf of FDA, the U.S. Attorney's Office had filed suit against Barr and some of its officers on June 12, 1992, to stop the company from manufacturing and distributing drugs FDA alleged to be substandard. FDA also sued to obtain a court-ordered recall of deficient batches of drugs already on the market and to require that Barr improve its manufacturing and laboratory practices. Barr agreed in July 1992 to suspend distribution of two-thirds of its products, which as a result were not covered by the court's decision.

While acknowledging that since the hearing began, Barr had made many of the improvements FDA identified as necessary, Judge Wolin noted that Barr's transformation from an "ugly duckling to a swan" was far from complete. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Court Decision Strengthens FDA's Regulatory Power
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Author Advanced search

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.